NLS Pharmaceutics files patent for novel sleep disorder treatment
Ticker: NCEL · Form: 6-K · Filed: Jun 11, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Jun 11, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: patent, pharmaceuticals, intellectual-property, drug-development
TL;DR
NLS Pharma just filed a patent for new narcolepsy drugs - big IP win!
AI Summary
On June 11, 2024, NLS Pharmaceutics Ltd. announced the publication of a new patent application for their next-generation dual non-sulfonamide orexin receptor agonists (DOXA). This patent application covers novel compounds designed to treat narcolepsy and other sleep-wake disorders.
Why It Matters
This patent filing is a crucial step in protecting NLS Pharmaceutics' intellectual property for their innovative DOXA compounds, potentially paving the way for future drug development and market exclusivity.
Risk Assessment
Risk Level: medium — Patent applications are a positive step, but the success of the drug and its commercial viability are still uncertain.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- June 11, 2024 (date) — Announcement date
- DOXA (drug_class) — Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists
FAQ
What is the primary focus of the new patent application filed by NLS Pharmaceutics?
The patent application focuses on next-generation dual non-sulfonamide orexin receptor agonists (DOXA) designed for treating narcolepsy and other sleep-wake disorders.
When was the press release announcing the patent application published?
The press release was published on June 11, 2024.
What is the significance of filing a patent application for DOXA compounds?
Filing a patent application is important for protecting NLS Pharmaceutics' intellectual property related to their novel compounds and could lead to future market exclusivity.
What type of disorders are the DOXA compounds intended to treat?
The DOXA compounds are intended to treat narcolepsy and other sleep-wake disorders.
Is this filing an annual report or a current report?
This filing is a Form 6-K, which is a Report of Foreign Private Issuer, filed for the month of June 2024.
Filing Stats: 302 words · 1 min read · ~1 pages · Grade level 12.2 · Accepted 2024-06-11 16:00:03
Filing Documents
- ea0207627-6k_nlspharma.htm (6-K) — 11KB
- ea020762701ex99-1_nlspharma.htm (EX-99.1) — 18KB
- 0001213900-24-051717.txt ( ) — 30KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: June 11, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 2